Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports Fourth Quarter and Fiscal 2024 Results; Provides Fiscal 2025 Guidance Boston, MA, May 9, 2024 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quart ...

Financial release accessible onlineBOSTON, May 9, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024, are available on its Investor Relations website.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 9, 2024. The conference call and webcast can be accessed with the following information: Teleconf ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Royal Philips (PHG) and Haemonetics (HAE) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis ...

In its upcoming report, Haemonetics (HAE) is predicted by Wall Street analysts to post quarterly earnings of $0.88 per share, reflecting an increase of 14.3% compared to the same period last year. Revenues are forecasted to be $326.95 million, representing a year-over-year increase of 7.4%.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ove ...

Haemonetics’ (HAE) major growth drivers include Plasma and the Hospital business. However, rising costs are a concern. The stock carries a Zacks Rank #3 (Hold) currently.Haemonetics’ Plasma business unit focuses on the collection of source plasma for pharmaceutical manufacturers using apheresis devices that only collect plasma. The demand for source plasma has been growing due to an expanding end-user market for plasma-derived biopharmaceuticals. The business also offers software solutions to support the op ...

Haemonetics (HAE) is likely to grow in the coming quarters due to its evolving Hospital portfolio, which is creating new opportunities for growth and diversification. The favorable prospects within the Plasma franchise also buoy optimism. The robust utilization of TEG disposables in the United States and China is driving revenues in Hemostasis Management, which is highly encouraging.Meanwhile, the impacts of economic uncertainties and foreign exchange remain concerns for the company’s operations.In the past ...

BOSTON, April 10, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 9, 2024.The call can be accessed via teleconference at: Q4 2024 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will rece ...

Haemonetics Corporation (HAE) announced receipt of the FDA 510(k) clearance for the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge expands Haemonetics' TEG 6s viscoelastic testing capabilities to include fully heparinized patients undergoing adult cardiovascular surgeries/procedures and liver transplants in both laboratory and point-of-care settings.The recent development will fortify Haemonetics’ portfolio of hemostasis diagnostic systems.More on TEG 6s Cartridge ...

BOSTON, April 4, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardio ...

Haemonetics Corporation (NYSE:HAE) Q3 2024 Earnings Conference Call February 8, 2024 8:00 AM ET Company Participants Olga Guyette – Senior Director-Investor Relations and Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call Participants Andrew Cooper – Raymond James Mike Matson – Needham & Company David Turkaly – JMP securities Operator Good day and thank you for standing by. Welcome to Haemonetics Corporation Third Quarter Fiscal 2024 Earnings Conference ...